[Clinical study of sodium dantroline (Dantrium) in multiple sclerosis (author's transl)].
The authors have studied the antispastic action of Dantrium in 50 patients with multiple sclerosis; in all cases, hypertonia, spasms or clonus constituted a severe obstacle to remedial therapy or nursing. After one year, the authors have found that Dantrium is effective in reducing hypertonia in 40% of the patients, in improving spasms in 65% and in reducing clonus in 50% of the cases. Secondary effects are fairly frequent (60%), characterized in most cases by diminished muscular strength and greater fatigability.
D002986:Clinical Trials as Topic; D003620:Dantrolene / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D009128:Muscle Spasticity / Q000188:drug therapy / Q000209:etiology; D013035:Spasm / Q000188:drug therapy / Q000209:etiology
D006827:Hydantoins; D003620:Dantrolene
Etude clinique du dantrolène sodium (Dantrium) dans la sclérose en plaques.